Key result
Nutraceuticals show promise for preventing cardiovascular disease and as add-on therapy to standard care.
Answers are grounded in this paper and cite their sources.
Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths. Current treatments for CVD, such as optimized statin therapy, are associated with considerable residual risk and several side effects in some patients. The outcome of research on the identification of alternative pharmaceutical agents for the treatment of CVD has been relatively disappointing with many promising leads failing at the clinical level. Nutraceuticals, products from food sources with health benefits beyond their nutritional value, represent promising agents in the prevention of CVD or as an add-on therapy with current treatments. This review will highlight the potential of several nutraceuticals, including polyunsaturated fatty acids, flavonoids and other polyphenols, as anti-CVD therapies based on clinical and pre-clinical mechanism-based studies.
No takes yet. Share an insight, caveat, or question.
Moss et al. (2018) conducted a review in Atherosclerosis and cardiovascular disease. Nutraceuticals (including polyunsaturated fatty acids, flavonoids, and other polyphenols) was evaluated. Nutraceuticals, including polyunsaturated fatty acids, flavonoids, and polyphenols, represent promising agents for preventing cardiovascular disease or as add-on therapy to current treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: